DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction Featuring Early Phase 2 FGR Results
Results Call • Phase 2Results call Fri, Oct 23, 2026, 8:00 AM ET
Company profile
DiaMedica Therapeutics Inc.
Pipeline2 assets
- DM199 (rinvecalinase alfa)DM199 / KLK1 / Recombinant human tissue kallikrein-1 protein (rhKLK1) / NeurologicalAcute Ischemic StrokePhase 2/3ReMEDy2 Study; in progress
- DM199 (rinvecalinase alfa)DM199 / KLK1 / Recombinant human tissue kallikrein-1 protein (rhKLK1) / Pregnancy ComplicationsPreeclampsiaPhase 2Part 1A Dose-Selection / Part 1B Expansion Cohort; in progressPreeclampsiaPhase 2Parts 2 & 3 Expected Management Study; in progressFetal Growth RestrictionPhase 2Part 3 Fetal Growth Restriction; in progress
Latest news12 items
All newsDiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
Results Call • Phase 2Results call Tue, Sep 1, 2026, 4:30 PM EDT
DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction
Trial Start • Phase 2Trial initiation Tue, Jun 23, 2026, 8:30 AM EDT
DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial
Enrollment • Phase 2/3Interim analysis completion Thu, Dec 31, 2026, 8:30 AM EDT